Last reviewed · How we verify
Autologous transplantation using rituxan/BEAM
Rituximab depletes B cells, followed by high-dose chemotherapy (BEAM regimen) and autologous stem cell transplantation to reset the immune system.
Rituximab depletes B cells, followed by high-dose chemotherapy (BEAM regimen) and autologous stem cell transplantation to reset the immune system. Used for Severe autoimmune diseases (e.g., systemic sclerosis, multiple sclerosis, systemic lupus erythematosus).
At a glance
| Generic name | Autologous transplantation using rituxan/BEAM |
|---|---|
| Also known as | Rituximab |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Drug class | Monoclonal antibody combined with high-dose chemotherapy and autologous stem cell transplantation |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Immunology / Hematology-Oncology |
| Phase | Phase 3 |
Mechanism of action
Rituximab is a monoclonal antibody targeting CD20 on B cells, causing their depletion. The BEAM chemotherapy regimen (carmustine, etoposide, cytarabine, melphalan) provides myeloablative conditioning. Autologous hematopoietic stem cell transplantation then restores bone marrow function with patient's own stem cells, effectively resetting the immune system to eliminate autoreactive B cells.
Approved indications
- Severe autoimmune diseases (e.g., systemic sclerosis, multiple sclerosis, systemic lupus erythematosus)
Common side effects
- Neutropenia
- Thrombocytopenia
- Infection
- Mucositis
- Nausea and vomiting
- Organ toxicity (cardiac, renal, hepatic)
Key clinical trials
- Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) (PHASE3)
- Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma (PHASE2)
- Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (PHASE2)
- Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: